Headlines about Arbutus Biopharma (NASDAQ:ABUS) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arbutus Biopharma earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 43.922860567574 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results – GlobeNewswire (press release) (globenewswire.com)
- Arbutus Biopharma (ABUS) Set to Announce Quarterly Earnings on Monday (americanbankingnews.com)
- Arbutus Biopharma Corp (ABUS) Given Average Recommendation of “Hold” by Analysts (americanbankingnews.com)
- Arbutus Biopharma (ABUS) Upgraded to “Hold” at BidaskClub (americanbankingnews.com)
Arbutus Biopharma (NASDAQ:ABUS) traded down $0.20 during mid-day trading on Wednesday, hitting $5.80. The stock had a trading volume of 36,437 shares, compared to its average volume of 161,868. The stock has a market capitalization of $333.07, a PE ratio of -1.21 and a beta of 1.02. The company has a quick ratio of 11.03, a current ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma has a 52-week low of $2.70 and a 52-week high of $8.25.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.